Date Published
January 2016

Page Count 
136

Additional Info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

  Human Microbiome Bundle

Human MicroBiome 2014

 

For Global Licenses, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Dan Miller
Marketing Associate
781-972-5492 

 




Table of Contents


Executive Summary  

History and Evolution  

Advances in Research on the Human Microbiome  

Commercial Activity 

Trends and conclusions  

CHAPTER 1

Introduction  

Scope and Structure of the Report  

CHAPTER 2

History and Evolution  

Exhibit 2.1 PubMed citations for the search term ‘human microbiome’  

CHAPTER 3

Advances in Research on the Human Microbiome  

Culture 

Systems Biology  

Microbial Ecology  

Synthetic Biology and Microbiome Engineering  

Diet  

The Virome  

Diagnostics  

Infectious Disease  

The microbiome in health and disease  

The Gut-Brain Axis 

Multiple Sclerosis  

Colorectal cancer  

The Microbiome at the Extremes of Life  

CHAPTER 4

Commercial Aspects of Microbiome Research and Development  

Selected Companies Active in the Microbiome Space  

Exhibit 4.1 Companies Active in the Microbiome Space  

AdvancingBio Inc.  

AOBiome LLC  

Assembly Biosciences, Inc.:  

AvidBiotics Corp.:  

C3 Jian, Inc.  

Diversigen, Inc.  

Eligo Bioscience  

Enterome Bioscience SA  

Evelo Therapeutics  

Evolve BioSystems Inc.  

ExeGi Pharma LLC  

Human Longevity, Inc.  

Interface Diagnostics  

Intrexon Corporation  

MaaT Pharma  

MetaboGen AB  

Microbiome Therapeutics LLC  

OpenBiome, Inc.  

Pureflora, Inc.  

Rebiotix Inc.  

Seres Therapeutics  

Symbiotic Health Inc.  

Symbiotix Biotherapies, Inc.  

Synlogic Therapeutics  

Synthetic Biologics Inc 

ViThera Pharmaceuticals Inc.  

Xycrobe Therapeutics, Inc.  

Deal Activity  

Exhibit 4.2 Deals  

4D Pharma – The Microbiota Company and GT Biologics  

4D Pharma and The APC Microbiome Institute UCC Ireland  

Ab-Biotics SA and Janssen Research and Development  

Enterome and Abbvie  

Enterome and Gustav Rouss 

Evelo Therapeutics and University of Chicago  

Intrexon Corporation and Oragenics Inc.  

Intrexon Corporation and Synthetic Biologics, Inc.  

Optibiotix and Venture Life  

Second Genome and APC Microbiome Institute University College Cork  

Second Genome and Evotec  

Seres Health and Nestlé  

Symbiotix and National Institute of Allergy and Infectious Diseases (NIAID)  

Synlogic and a Global Pharmaceutical Partner  

Vedanta Biosciences and Janssen Research and Development  

CHAPTER 5

Market Dynamics  

Exhibit 5.1 Respondents’ Subject Matter Category inMicrobiome R&D  

Exhibit 5.2 Type of Organization Where Respondents Work  

Exhibit 5.3 Further description of type of company where respondents work  

Exhibit 5.4 Respondents’ Position/Designation at the Workplace  

Exhibit 5.5 Type of Work Currently Performed by Respondents  

Exhibit 5.6 Type of Work Respondents Will Likely Perform in the Next Year  

Exhibit 5.7 Respondents’ Current Research Focus by Body Site/Niche  

Exhibit 5.8 Respondents’ Current Research Focus by Therapeutic Area  

Exhibit 5.9 Respondents’ Current Research Focus by Disease Condition  

Exhibit 5.10 Respondents’ Current or Future Research Focus by Product  

Exhibit 5.11 Respondents’ Expectation of Change in Their Organization’s Microbiome Involvement in the Next Two Years  

Exhibit 5.12 Respondents’ Opinion Regarding Academic Participation in Developing New Concepts for Rx and/or Dx of Dysbiosis  

Exhibit 5.13 Respondents’ Level Agreement with Statement: Current Methods are Adequate for Quantitative Characterization 

of the Microbiome for Personalized Medicine  

Exhibit 5.14 Respondents’ Level Agreement with Statement: Sufficient Information about the Composition and Function of Human Microbiomes 

has been Gathered to Justify Translational R&D  

Exhibit 5.15 Respondents’ Current Research Work on Detecting Dysbiosis Uses the Following Techniques  

Exhibit 5.16 Respondents’ Opinion on the Potential of Microbiome R&D to Provide Major Contributions to Healthcare  

Exhibit 5.17 Respondents’ Level of Agreement with the Statement: "Recent Findings Relating the Microbiome to Health and Disease 

Will Enable an Important New Generation of Therapies for a Number of Chronic Diseases.”  

Exhibit 5.18 Respondents’ Level of Agreement With the Statement: "Recent Findings Relating the Microbiome to Health and Disease 

Will Provide an Important New Generation of Measures to Maintain Good Health."  

Exhibit 5.19 Respondents’ Level of Agreement With the Statement: "It is Still Early Days for Translational Interventions Based on Microbiome R&D, 

and More Years of Research are Necessary to Establish its Potential."  

Exhibit 5.20 Respondents’ Level of Agreement With the Statement: "Sequencing Technologies Will Remain Dominant Over Microarrays 

for Most Microbiome Diagnostic Applications."  

Exhibit 5.21 Respondents’ Level of Agreement With the Statement: "Big Pharma Involvement in Microbiome-related R&D Will Increase Significantly 

Over the Next Decade.”  

Exhibit 5.22 Respondents’ Level of Agreement With the Statement: "We Can Expect a Flood of New Rationally Designed and/or 

Personalized Biotherapeutics to Emerge During the Next Decade."  

 

CHAPTER 6

Observations and Conclusions  

Microbiome Market Potential  

Synthetic Biology  

Dysbiosis and Disease – Establishing Causality Over Correlation  

Consistency of Results Across Laboratories  

Future Directions  

 

CHAPTER 7

Interview Transcripts  

Lee Jones, Founder CEO, Rebiotix  

Brian Varnum, PhD, Chief Development Officer C3 Jian  

Yanjiao Zhou, MD, PhD, Research Scientist, The Jackson Laboratory for Genomic Medicine, Farmington CT  

Dr Bernard Malfroy-Camine, President and CEO, ViThera Pharmaceuticals  

Mark L. Heiman, Ph.D., FTOS, Vice President, Research and CSO, MicroBiome Therapeutics (formerly NuMe Health)  

Larry Weiss, MD, Chief Medical Officer, AOBiome, LLC  

Karen E. Nelson, PhD, President, J. Craig Venter Institute (JCVI), Head, Microbiome Program, Human Longevity Institute (HLI)  

Sara Malcus, PhD, CEO, MetaboGen AB  

References  

About CHI